Yi Luo

Prof. Dr. Yi Luo


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YWYongya Wu
Yongya Wu
AWAoxue Wang
Aoxue Wang
GFGuotai Feng
Guotai Feng
XPXiaoli Pan
Xiaoli Pan
WSWen Shuai
Wen Shuai
GWGuan Wang
Guan Wang

20 June 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YYYu Yang
Yu Yang
QYQian Yao
Qian Yao
DSDan Song
Dan Song
KTKexin Tang
Kexin Tang
ZTZijun Tang
Zijun Tang
YXYongmei Xie
Yongmei Xie

12 September 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HZHaoxuan Zhou
Haoxuan Zhou
MHMingxing Hu
Mingxing Hu
HJHui Jie
Hui Jie
YLYujue Li
Yujue Li
KTKexin Tang
Kexin Tang
YXYongmei Xie
Yongmei Xie

15 April 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CFChen Fan
Chen Fan
YWYijie Wang
Yijie Wang
HHHui Huang
Hui Huang
WLWenzhen Li
Wenzhen Li
JMJialin Ma
Jialin Ma
JGJian Gu
Jian Gu
Breast cancer is the most common malignancy in women and is a molecularly heterogeneous disease. Signal transducer and activator of transcription 3 (Stat3) is overexpressed and hyperactivated in a variety of human tumours, including breast cancer, thus representing a promising target for breast cancer treatment. In the present study, we evaluated the activities of a novel Stat3 inhibitor named Statmp-151 in the human breast cancer cell lines MCF-7 and MDA-MB-231 and the murine mammary carcinoma cell line 4T1. The in vitro results showed that Statmp-151 inhibited the proliferation of breast cancer cell lines in a dose- and time-dependent manner and suppressed the phosphorylation of Stat3 in a dose-dependent manner. Flow cytometry (FCM) assays revealed that Statmp-151 affected mitochondrial membrane potential and reactive oxygen species (ROS) production. Furthermore, Statmp-151 inhibited cell migration, as shown by analysis of the matrix metalloproteinases MMP2 and MMP9. Finally, in a 4T1 tumour-bearing mouse model, intraperitoneal injection of 30 mg/kg/day Statmp-151 significantly suppressed the growth of tumours without obvious toxicity. These results indicated that Statmp-151 might be a potential candidate for the treatment of breast cancer.

1 November 2019 in Dyes and Pigments
Verified
Journal Article
Closed access
XCXiuli Chen
Xiuli Chen
WPWentao Peng
Wentao Peng
SHShenzhen Huang
Shenzhen Huang
CYChao Yang
Chao Yang
MHMingxing Hu
Mingxing Hu
KLKun Li
Kun Li

9 June 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
XSXingping Su
Xingping Su
ZLZhihao Liu
Zhihao Liu
LYLin Yue
Lin Yue
XWXiuli Wu
Xiuli Wu
WWWei Wei
Wei Wei
YZYiwen Zhang
Yiwen Zhang
Abnormal activation of FGFR signaling pathway plays an essential role in various types of tumors. Therefore, targeting FGFRs represents an attractive strategy for cancer therapy. Herein, we report a series of 1H-pyrrolo[2,3-b]pyridine derivatives with potent activities against FGFR1, 2, and 3. Among them, compound 4h exhibited potent FGFR inhibitory activity (FGFR1–4 IC50 values of 7, 9, 25 and 712 nM, respectively). In vitro, 4h inhibited breast cancer 4T1 cell proliferation and induced its apoptosis. In addition, 4h also significantly inhibited the migration and invasion of 4T1 cells. Furthermore, 4h with low molecular weight would be an appealing lead compound which was beneficial to the subsequent optimization. In general, this research has been developing a class of 1H-pyrrolo[2,3-b]pyridine derivatives targeting FGFR with development prospects.